Similarly, BCL2 inhibitors like venetoclax are highly effective in TP53-mutated CLL, but resistance can emerge due to mutations in BCL2 itself, leading to therapeutic failure [201]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.